Robotic partial nephrectomy appears to be a reasonable option for certain renal masses, provided that an experienced surgeon performs the procedure at a center that can manage postoperative complications, researchers concluded after conducting an analysis involving nearly 1,800 individuals. Participants had cT1a (n=1358), cT1b (n=379), or cT2a (n=41) renal masses. Investigators looked at how intra and postoperative outcomes in patients with cT2a masses compared to those with the other 2 mass types. Among the results:
- Performing robotic surgery on cT2a vs cT1a masses resulted in a 12% longer operative time, 32% increase in estimated blood loss, 7% increase in ischemia time, nearly 4-fold higher odds of acute kidney injury at discharge, and a nearly 11-fold higher recurrence risk.
- Performing the procedure on cT2a vs cT1b masses resulted in a 12% increase in blood loss.
- Operative time and recurrence risk were not statistically different.
- Complications, positive margins, length of stay, and renal function decline up to 2 years post-procedure were not statistically different.
Delto J, Paulucci D, Helbig M, et al. Robotic partial nephrectomy for large renal masses: A multi-institutional series. [Published online ahead of print January 22, 2018]. BJU Int. doi:10.1111/bju.14139.
This Week's Must Reads
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32
Must Reads in Renal Cell Carcinoma
Obesity tied to higher risk of clear cell RCC, Callahan CL et al. Cancer Epidemiol. 2018 Jul 18. doi: 10.1016/j.canep.2018.07.002
Partial nephrectomy for localized RCC, Cahn D et al. AUA Annual Meeting, Abstract PD07-04
RFA for small renal tumors holds up over long term, Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045
Pazopanib active in von Hippel-Lindau disease neoplasms, Jonasch E et al. Lancet Oncol. 2018 Sep 17. doi: 10.1016/S1470-2045(18)30487-X
Improved RCC survival attributed to better therapy, not earlier diagnosis, Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023